Syndax Pharmaceuticals, Inc. SNDX

Citi forecasts up to 410% rally for Syndax Pharmaceuticals (SNDX) and names it a strong buy stock. Citi's 410% upside forecast for SNDX will drive major positive shifts in investor sentiment and stock trajectory.

Syndax Pharmaceuticals nearly doubled sales yet its stock declined after the results. Doubled sales show revenue growth but the stock drop signals possible concerns over margins or outlook that may moderate near-term performance.

Syndax Pharmaceuticals, Inc. (SNDX) held its Q2 2026 earnings call, covering financial results, operational updates, and outlook. Quarterly earnings calls deliver financial and strategic updates that can moderately shift near-term investor sentiment and valuation.

Syndax Pharmaceuticals reports surging Revuforj and Niktimvo sales with narrowing losses that could strengthen investor sentiment and support future stock gains. Strong commercial traction from key product sales and improving financials can materially lift company trajectory and valuation.

Syndax Pharmaceuticals Inc reported 92% revenue growth in Q2 2026 earnings call highlights amid ongoing operational and pipeline developments. 92% revenue surge points to major financial gains likely to shift company trajectory and investor sentiment.

Syndax Pharmaceuticals reported Q2 financial results and pipeline progress in its earnings call, including updates on revumenib and axatilimab development timelines and cash position. Q2 earnings and pipeline updates may influence near-term investor views but are unlikely to fundamentally shift company trajectory.

Syndax Pharmaceuticals reported a Q2 loss and missed revenue estimates. Q2 loss and revenue miss affects reported financial performance.

Syndax Pharmaceuticals reported second quarter 2026 financial results and provided a business update. Quarterly earnings releases and business updates deliver key financial metrics and pipeline progress that can shift near-term stock valuation.

Syndax Pharmaceuticals advances pipeline development in lung cancer and myelofibrosis to expand beyond Revuforj and support future growth. Pipeline expansion into new indications represents major strategic moves that can significantly alter company trajectory.

Syndax Pharmaceuticals will highlight late-stage programs and unveil new pipeline assets at an R&D event. Unveiling new pipeline assets signals major growth potential and shifts in company trajectory.

Wall Street analysts project Syndax Pharmaceuticals (SNDX) stock could surge 70.38%. Analyst surge projections can drive SNDX trading volumes and price movements.

Revised AML market estimates prompt reevaluation of Syndax Pharmaceuticals (SNDX) as a biotech investment opportunity. Revised AML market estimates may alter SNDX financial outlook and investor sentiment without transforming core operations.

Syndax Pharmaceuticals stock rises 5.2% on strong all-oral Revuforj SAVE trial data. Positive Revuforj trial results advance drug pipeline and lift stock trajectory.

Syndax showcases revumenib clinical activity in multiple acute leukemia subtypes and settings at EHA 2026. Revumenib data presentation at EHA 2026 signals major leukemia treatment progress for Syndax.

Syndax Pharmaceuticals published SAVE trial data in the Journal of Clinical Oncology demonstrating Revuforj (revumenib) combined with decitabine/cedazuridine and venetoclax benefits patients with relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML. Publication of positive SAVE data for revumenib in key AML subtypes in a major journal strengthens the drug's clinical profile and supports potential market adoption.

Syndax Pharmaceuticals raises $250 million via private placement of convertible senior notes. Securing $250 million strengthens balance sheet and funds pipeline development.

Syndax Pharmaceuticals highlighted Revuforj (revumenib) data at ASCO 2026, including an oral presentation of post-transplant results. Oral presentation of clinical data on lead asset at major oncology meeting signals potential for meaningful shifts in company trajectory and sentiment.

Syndax Pharmaceuticals announced acceptance of four revumenib abstracts for ASCO 2026, including an oral presentation on post-transplant data. Oral ASCO presentation on revumenib post-transplant data raises pipeline visibility and may lift near-term investor sentiment.

Syndax Pharmaceuticals announces 12 abstracts on Revuforj (revumenib) accepted for EHA 2026, advancing its leadership in Menin inhibition. 12 abstracts at EHA 2026 signal Revuforj progress and bolster SNDX's competitive position in Menin inhibition without immediate transformative data.

Syndax Pharmaceuticals (SNDX) narrows losses as Revuforj and Niktimvo gain traction, prompting analysis of underlying shifts. Revuforj and Niktimvo gaining traction narrows losses, signaling significant revenue potential and positive trajectory shift.

Syndax Pharmaceuticals Inc (SNDX) reported record revenue growth in Q1 2026 earnings call, highlighting strong financial performance and positive developments. Record revenue growth in Q1 2026 earnings signals major positive shift in financial trajectory and investor sentiment for SNDX.

Syndax Pharmaceuticals released highlights from its Q1 earnings call, covering financial results, pipeline updates, and forward guidance. Q1 earnings call highlights provide critical insights into financial health, clinical progress, and strategic outlook directly shaping SNDX's stock performance and investor confidence.

Syndax Pharmaceuticals, Inc. (SNDX) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates for biotech firms like SNDX often reveal pipeline progress, cash runway, and strategic shifts that significantly sway investor sentiment and stock trajectory.

Syndax Pharmaceuticals (SNDX) biotech stock surges 72% amid an $8 million sale, yet one fund remains bullish on its prospects. 72% stock surge signals significant boost to market performance and investor sentiment despite the $8 million sale.

Syndax Pharmaceuticals (SNDX) stock surges 365% following an $8 million investment targeting a drug with three planned NDA filings. SNDX stock's 365% surge from $8M investment in drug with three planned NDA filings signals major regulatory and growth potential.

Syndax Pharmaceuticals Inc. (SNDX) stands on a strong footing driven by robust demand for its key flagship drugs. Robust demand for flagship drugs indicates significant positive impact on revenue and market performance.

Syndax Pharmaceuticals (SNDX) leverages ESOP shares and new drugs to quietly redefine its investment story. ESOP shares and new drugs enable major strategic shifts that could significantly enhance SNDX's market performance and investor sentiment.

Syndax Pharmaceuticals (SNDX) released Q4 2025 earnings call transcript detailing financial results, pipeline progress, operational updates, and future outlook. Q4 earnings call transcript reveals financial performance, guidance, and strategic updates that significantly influence SNDX's trajectory and investor sentiment.

Syndax Pharmaceuticals reported Q4 2025 earnings with key financial results, pipeline updates on cancer therapies like revumenib, clinical trial progress, and forward guidance amid regulatory milestones. Q4 earnings highlighted pipeline advancements and financial outlook poised to significantly shift SNDX's competitive positioning and investor sentiment.

Syndax Pharmaceuticals released Q4 earnings call highlights, detailing financial results, clinical trial updates, pipeline progress, and 2024 guidance. Q4 earnings highlights cover financial performance, pipeline advancements, and forward guidance with potential to significantly influence investor sentiment and stock trajectory.